The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.
AffiliationCancer Research UK Department of Medical Oncology, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractT cells genetically engineered to express tumour-targeting receptors are attractive anti-cancer therapeutic agents. Human T cells engrafted with a chimeric receptor specific for the B-cell lymphoma antigen CD19 fused to the CD3zeta receptor (aCD19z) are functional in vitro. Current successful clinical protocols targeting melanoma use pre-conditioning chemotherapy in combination with T cells. This study demonstrated that interleukin-2 expanded aCD19z T cells combined with cyclophosphamide effectively treated five-day established Raji B-cell lymphoma in an immunocompromised model system with 50% of mice surviving >100 days. This observation strongly supports the combination of antibody targeted T cells with chemotherapy as a novel approach for the therapy of CD19(+) B-cell malignancies.
CitationThe combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-Cell lymphoma. 2008, 142 (1):65-8 Br. J. Haematol.
JournalBritish Journal of Haematology
- Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.
- Authors: Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE
- Issue date: 2009 Apr
- Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
- Authors: Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga S, Takihara Y, Kimura A
- Issue date: 2010 Oct
- A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
- Authors: Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH
- Issue date: 1997 Mar 15
- Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
- Authors: Bohlen H, Manzke O, Titzer S, Lorenzen J, Kube D, Engert A, Abken H, Wolf J, Diehl V, Tesch H
- Issue date: 1997 May 1
- Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
- Authors: Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, Al-Kadhimi Z, Forman SJ, Gillies SD, Jensen MC, Colcher D, Raubitschek A, Cooper LJ
- Issue date: 2007 Mar 15